Clinical Trials Logo

Clinical Trial Summary

The purpose is to investigate if different microparticles and markers of hemostasis predict outcome after TIA or ischemic stroke and to study the association between these variables and stroke subtype or etiology.


Clinical Trial Description

1. Introduction Within a previous study ('PROPPSTOPP') a cohort of 249 patients with ischemic stroke (IS) or TIA was established in Stockholm between 2007 and 2009. The original aims were twofold: 1) to look for occult atrial fibrillation (completed, NTC01160406) and 2) to investigate microparticle levels and markers of hemostasis in the acute phase and one month after symptoms. Blood samples were taken on both occasions. Patients were found to have higher microparticle levels and increased thrombin generation in plasma both acutely and at one month as compared to healthy controls. This follow-up study will investigate the prognostic ability of microparticles (primary variables) and markers of hemostasis (secondary variables) to predict outcome as documented in hospital records and Swedish registers. The association between microparticles/coagulation markers and stroke subtype/etiology will also be investigated. 2. Variables 2.1 Microparticles Microparticles are membrane vesicles (0.1-1.0 µm) released from cells at activation or apoptosis. They carry surface markers from the releasing cell. Microparticles are of interest as biomarkers for activation of cells in the circulation, e g platelets, endothelial cells or leukocytes. They may have pro-coagulant properties. For this study the following microparticles and surface markers have been analyzed: - Total number of microparticles (MP's) - Number of MP's exposing phosphatidylserine (PS) (pro-coagulant property) - Number of MP's of any type exposing tissue factor (TF), with or without simultaneous exposure of PS (pro-coagulant properties, activation of monocytes/endothelium) - Number of platelet microparticles (PMP's), identified by surface exposure of GPαIIb (CD41), with or without simultaneous exposure of PS (platelet activation) - Number of PMP's exposing P-selectin with or without simultaneous exposure of PS (platelet activation) - Number of PMP's exposing TF with or without simultaneous exposure of PS (pro-coagulant properties) 2.2 Markers of hemostasis Different variables of importance for coagulation, platelet activation, fibrinolysis and inflammation were measured in the original study, namely: - Prothrombin fragment F1+2 - Thrombin generation by Calibrated Automated Thrombin generation (CAT) - Microparticle-pellet induced thrombin generation 3. Outcome 3.1 Primary outcome The primary outcome is new ischemic events, i e fatal or non-fatal recurrent ischemic stroke, myocardial infarction or ischemic cardiovascular death in the time frame 2007-2014. Diagnoses will be retrieved from the following sources: - The Swedish Register for Cause of death - The Swedish Register of in-house hospital care - Medical records at recruiting hospitals. 3.2 Secondary outcome Secondary outcomes are recurrent ischemic stroke respectively all-cause mortalitý as documented in the sources above. 4. Statistical Methods The statistical analysis of the prospective cohort study will be performed in steps: 1. Descriptive statistics comparing averages/medians of the above variables for patients with and without outcome. 2. For variables with p-values < 0.2 in step 1: univariate event-free survival Kaplan-Meyer curves by variable median split. Probability calculations of differences by log-rank test. 3. Multivariate analysis by Cox regression analysis including the most significant variables in step 2 and established cardiovascular risk factors. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05524506
Study type Observational
Source Karolinska Institutet
Contact
Status Completed
Phase
Start date June 2007
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01955642 - Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke N/A
Recruiting NCT01541163 - Heart and Ischemic STrOke Relationship studY N/A
Recruiting NCT06076122 - Salicornia for Neurovascular Health Improve N/A
Not yet recruiting NCT04386525 - Omega 3 and Ischemic Stroke; Fish Oil as an Option Phase 4
Recruiting NCT06270927 - A Feasibility Study for Randomization of Code Stroke Imaging Strategies
Completed NCT02912546 - Cerebral Perfusion Associated With Postural Changes: an ASL MR Perfusion Study N/A
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Completed NCT05815836 - Precision Medicine in Stroke
Recruiting NCT01673932 - Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke Phase 1
Recruiting NCT01556802 - Use of Minocicline in Patients With Stroke Phase 1
Completed NCT02101606 - Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke Phase 2
Completed NCT00829361 - Stroke Telemedicine for Arizona Rural Residents Trial N/A
Terminated NCT00073372 - A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II) Phase 3
Recruiting NCT04908241 - Telerehabilitation With Aims to Improve Lower Extremity Recovery Post-Stroke (TRAIL-RCT) N/A
Recruiting NCT04188132 - EEG Based BCI for Upper Limb Rehabilitation in Stroke N/A
Completed NCT01713491 - Pre-stroke Cognitive Status and Thrombolytic Therapy N/A
Completed NCT01443962 - The Effect of Positive End Expiratory Pressure (PEEP) During Laparoscopic Cholecystectomy N/A
Terminated NCT01059149 - Safety and Long-term Effectiveness of High Frequency Repetitive Transcranial Magnetic Stimulation of Stroke (RAICup) Phase 2